hVIVO
hVIVO plc

hVIVO plc share price, company news, analysis and interviews

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Venn Life Sciences is an Integrated Drug Development partner offering a unique combination of drug development consultancy, clinical trial design and execution.

FluCamp is all about improving the health of the population, through increasing understanding around common viral illnesses.

Imutex Limited, formed in 2016, is a joint venture between PepTcell and hVIVO, to accelerate the development of a Broad-Spectrum ‘Universal’ Influenza Vaccine, FLU-v, and a Mosquito-Borne Diseases Vaccine, AGS-v.

hVIVO plc 5 day trade history

Share this page

Twitter
LinkedIn
Facebook
Email
WhatsApp
hVIVO

hVIVO plc share price

Fundamentals

52 Week High / Low

Analyst Notes & Comments

Questions & Answers

More Information

Latest hVIVO plc News

Interviews

Questions & Answers

Broker Notes & Comments

hVIVO plc share price

Fundamentals

Share this page

Twitter
LinkedIn
Facebook
Email
WhatsApp

Data policy – All information should be used for indicative purposes only. You should independently check data before making any investment decision and or seek professional advice. DirectorsTalk cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used.